Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors (KEYNOTE-603)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03313778
Recruitment Status : Recruiting
First Posted : October 18, 2017
Last Update Posted : June 7, 2021
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
ModernaTX, Inc.

Brief Summary:
The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in participants with resected solid tumors and in combination with pembrolizumab in participants with unresectable solid tumors.

Condition or disease Intervention/treatment Phase
Solid Tumors Biological: mRNA-4157 Biological: Pembrolizumab Phase 1

Detailed Description:
This is a multi-part, dose-escalation study of mRNA-4157 monotherapy in participants with resected solid tumors (Part A) and of mRNA-4157 in combination with pembrolizumab in participants with both unresectable (locally advanced or metastatic) solid tumors (Parts B and C) and resected cutaneous melanoma (Part D). Parts A and B will include a dose escalation phase of the study to identify doses of mRNA-4157 for the expansion phase of the study. Doses of mRNA-4157 will be administered to participants in a dose escalation regimen. Participants in Parts B, C, and D dose expansion phase will receive mRNA-4157 at a recommended dose for expansion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 142 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors
Actual Study Start Date : August 14, 2017
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : June 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Part A: Dose Escalation
Participants will receive a fixed applicable dose of mRNA-4157 administered via an intramuscular (IM) injection on Day 1 of each 21-day cycle for up to 9 cycles.
Biological: mRNA-4157
Personalized cancer vaccine, IM injection

Experimental: Part B: Dose Escalation
Participants will receive a fixed applicable dose of mRNA-4157 administered via an IM injection on Day 1 of each 21-day cycle for up to 9 cycles and fixed-dose of pembrolizumab via IV infusion on Day 1 of each 21-day cycle until progression, unacceptable toxicity, or up to 35 cycles (approximately 2 years of treatment), whichever is sooner.
Biological: mRNA-4157
Personalized cancer vaccine, IM injection

Biological: Pembrolizumab
Intravenous infusion

Experimental: Part A: Dose Expansion
Participants will receive mRNA-4157 via IM injection at an applicable dose, identified during the dose escalation phase of the study, on Day 1 of each 21-day cycle for up to 9 cycles.
Biological: mRNA-4157
Personalized cancer vaccine, IM injection

Experimental: Part B, C, and D: Dose Expansion
Participants will receive mRNA-4157 via IM injection at an applicable dose, identified during the dose escalation phase of the study, on Day 1 of each 21-day cycle for up to 9 cycles. Participants will also receive a fixed-dose of pembrolizumab via IV infusion on Day 1 of each 21-day cycle until progression, unacceptable toxicity, or up to 35 cycles (approximately 2 years of treatment), whichever is sooner.
Biological: mRNA-4157
Personalized cancer vaccine, IM injection

Biological: Pembrolizumab
Intravenous infusion




Primary Outcome Measures :
  1. Number of Participants with Adverse Events [ Time Frame: Part A: Baseline through 100 days after last mRNA-4157 dose; Parts B, C, and D: Baseline through 90 days after last pembrolizumab dose ]

Secondary Outcome Measures :
  1. Percent Change from Baseline of Biomarker Levels in Tumors at Day 50 [ Time Frame: Baseline, Day 50 ]
  2. Antigen-Specific T-cell Responses in Peripheral Blood [ Time Frame: Baseline through 100 days after last mRNA-4157 dose ]
  3. Part C: Overall Response Rate (ORR): Number of Participants with Tumor Response (Partial or Complete) [ Time Frame: Baseline through 30 days after the last dose of mRNA4157 and/or pembrolizumab ]
  4. Part C: Duration of Response (DoR) [ Time Frame: Baseline through 30 days after the last dose of pembrolizumab ]
    DoR is defined as time from first tumor response (partial or complete) until either radiological disease progression, clinical/symptomatic disease progression or death (whichever is sooner).

  5. Part C: Progression Free Survival (PFS) [ Time Frame: Baseline through 30 days after the last dose of pembrolizumab ]
    PFS is defined as time between the date of first dose of pembrolizumab and the date of either radiological disease progression, clinical/symptomatic disease progression or death (whichever is sooner).

  6. Part C: Overall Survival (OS) [ Time Frame: Baseline through 30 days after the last dose of pembrolizumab ]
    OS is defined as time between the date of the first dose of study drug and the date of death due to any cause.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, ≥18 years old with the ability to understand and provide signed and witnessed informed consent, and agree to comply with protocol requirements
  • Part A: Participants must have one of the histologically-confirmed solid malignancies listed below, must be clinically disease-free at study entry (that is, participants in the adjuvant setting). Participants will be permitted to complete any standard of care adjuvant therapy prior to study entry, and those not eligible for any standard of care adjuvant treatment or who decline such treatment are permitted to consent to this study, as long as all treatment options have been transparently disclosed and documented in the participant's medical record.
  • Part B: Participants must have one of the histologically- or cytologically-confirmed unresectable (locally advanced or metastatic) solid malignancies listed below, have measurable disease at study entry defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1., and be considered suitable for treatment with pembrolizumab; in this study pembrolizumab will be considered an investigational study drug.

Participants with any of the following solid malignancies:

a. Non-small cell lung cancer (participants in Part B must either lack epidermal growth factor receptor (EGFR) sensitizing mutation or anaplastic lymphoma kinase (ALK) translocation per local test results or must have progressed on approved standard of care treatment for EGFR or ALK positive non-small cell lung cancer [NSCLC]) b. Small cell lung cancer c. Melanoma d. Bladder urothelial carcinoma e. Human papillomavirus-negative head and neck squamous cell carcinoma (HPV-ve HNSCC) f. Any solid malignancy known to be microsatellite instable (MSI) high/mismatch repair (MMR) deficient g. Any solid malignancy known to have a high tumor mutational load/burden

  • Part C: Participants must have one of the histologically- or cytologically confirmed unresectable (locally advanced or metastatic) solid malignancies listed below, must not have received prior anti-programmed cell death protein 1 (PD-1)/programmed death -ligand 1 (PD-L1) therapy, and must have measurable disease at study entry defined by RECIST 1.1.

    1. Microsatellite stable (MSS)-CRC
    2. HPV-ve metastatic or recurrent HPV-ve HNSCC of the oral cavity, oropharynx, hypopharynx, or larynx
    3. Bladder urothelial carcinoma
  • Part D: Participants must have completed resected adjuvant melanoma and must be clinically disease-free at study entry. Participants will be permitted to complete any standard of care adjuvant therapy prior to study entry, and those not eligible for any standard of care adjuvant treatment or who decline such treatment are permitted to consent to this study, as long as all treatment options have been transparently disclosed and documented in the participant's medical record.
  • Parts A and D: Participants must have a formalin-fixed paraffin embedded (FFPE) tumor sample available (for example, from their prior surgery) that is suitable for the next generation sequencing (NGS) required for this study.
  • Parts B and C: Participants must have at least 1 lesion amenable to the mandatory fresh tumor biopsy at study entry and provide a biopsy suitable for the next generation sequencing (NGS) required for this study. An existing (archival) FFPE tumor sample may instead be used for NGS after discussing with medical monitor.
  • Participants must have resolution of toxic effect(s) from prior therapy to Grade 1 or less. Participants with Grade ≤2 neuropathy or alopecia are an exception to this criterion. If a participant received major surgery or radiation therapy of >30 gray (Gy), they must have recovered from the toxicity and/or complications from the intervention to Grade 1 or less.
  • Participant is willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug (male and female participants of childbearing potential).
  • Participants with Performance Scale (PS) of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) PS
  • Life expectancy >12 weeks at Screening
  • Participants with adequate organ and marrow function
  • Parts A and D: Participant must consent to required apheresis procedure and meet additional inclusion criteria per local institutional apheresis procedure.

Exclusion Criteria:

  • Treatment with any of the following:

    1. Any investigational agents, anti-cancer monoclonal antibody, anti-cancer therapeutic vaccine, immunostimulant (for example, IL-2), or study drugs from a previous clinical study within 4 weeks of the first dose of mRNA-4157 or pembrolizumab (note only a 2 week wash out is required from prior pembrolizumab treatment)
    2. Any chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks of the first dose of mRNA-4157 or pembrolizumab
    3. Live-virus vaccination within 30 days of the first dose of mRNA-4157 or pembrolizumab. Seasonal flu vaccines that do not contain live virus are permitted.
    4. Any systemic steroid therapy or other form of immunosuppressive therapy within 7 days of the first dose of mRNA-4157 or pembrolizumab
    5. Transfusion of blood products (including platelets or red blood cells [RBCs]) or administration of colony stimulating factors (including granulocyte colony stimulating factor [G-CSF], granulocyte/macrophage colony stimulating factor [GM-CSF], or recombinant erythropoietin) within 1 week of the NGS blood sample during screening, and 4 weeks of the first dose of mRNA-4157 or pembrolizumab
  • Prior PD-1/PD-L1 treatment is permitted for participants in Parts A, B, and D of this study, but only participants who have progressed on their prior PD-1/PD-L1 treatment without a partial or complete response, and without discontinuing for drug-related toxicity are eligible.
  • Active central nervous system metastases and/or carcinomatous meningitis
  • Active autoimmune disease that has required systemic treatment in past 2 years
  • Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis
  • Has a diagnosis of immunodeficiency
  • Any clinically-significant cardiac disease defined as New York Heart Association Class III or IV within the past 6 months of Screening, unless, in the opinion of the Investigator, the disease is well-controlled
  • A history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator
  • Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Previously identified hypersensitivity to components of the formulations used in this study
  • Had a solid organ or allogeneic bone marrow transplant
  • Participants with a history of interstitial lung disease
  • An active infection requiring systemic therapy
  • A known history of human immunodeficiency virus (HIV)
  • Known active Hepatitis B or Hepatitis C
  • Known additional malignancy that is progressing or requires active treatment, exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone curative therapy, or in situ cervical cancer
  • Participants participating in apheresis; mandatory in the Part A apheresis expansion phase cohort and Part D (optional for other study parts), must not meet any of the exclusion criteria on any day when apheresis is performed, either protocol specific apheresis criteria, or per local institutional apheresis protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03313778


Contacts
Layout table for location contacts
Contact: Moderna Clinical Trials 877-913-3286 clinicaltrials@modernatx.com

Locations
Layout table for location information
United States, Arizona
University of Arizona Recruiting
Tucson, Arizona, United States, 85721
Contact    520-694-9057      
United States, Florida
Florida Cancer Specialists Recruiting
Sarasota, Florida, United States, 34232
Contact    352-339-7000      
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact    877-726-5130      
United States, New Jersey
John Theurer Cancer Center Recruiting
Hackensack, New Jersey, United States, 07601
Contact    551-996-5855      
United States, New York
NYU Langone Recruiting
New York, New York, United States, 10016
Contact    212-263-4432      
United States, North Carolina
Duke Cancer Institute Recruiting
Durham, North Carolina, United States, 27710
Contact    888-275-3853      
United States, Tennessee
Sarah Cannon Research Institute, Tennessee Oncology Recruiting
Nashville, Tennessee, United States, 37203
Contact    615-514-2401      
Sponsors and Collaborators
ModernaTX, Inc.
Merck Sharp & Dohme Corp.
Layout table for additonal information
Responsible Party: ModernaTX, Inc.
ClinicalTrials.gov Identifier: NCT03313778    
Other Study ID Numbers: mRNA-4157-P101
First Posted: October 18, 2017    Key Record Dates
Last Update Posted: June 7, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ModernaTX, Inc.:
mRNA-4157
Personalized cancer vaccine
PCV
pembrolizumab
Moderna
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents